Melvin is also a Director of Catalent Pharma Solutions and was Chairman of the Board of PRA International, Inc. and eResearch Technology, Inc.
Mel is retired President and Chief Operating Officer of MedImmune, Inc. He was a member of the Board of Directors for MedImmune, Inc. from November 1998 through March 2005 and was the company’s President and Chief Operating Officer from 1998 to 2004. MedImmune, acquired by AstraZeneca Plc in June 2007, is focused on pediatric infectious diseases, cancer and inflammatory diseases.
Prior to joining MedImmune, Mel Booth was President and Chief Operating Officer of Human Genome Sciences, Inc. where he was also a member of the Executive Committee and Board of Directors. From 1975 to 1995, he was employed at Syntex Corporation. He held a variety of positions, including President of Syntex Laboratories, Inc., President of Syntex, Inc., Canada and Vice President of Syntex Corporation.
Mel Booth has been active in U.S. pharmaceutical industry organizations and is a past Chairman of the Pharmaceutical Manufacturers Association of Canada. He currently serves as a Chairman of Mallinckrodt and a Director on the board of Ventria BioScience, and was recently the Lead Director of Millipore Corporation, acquired by Merck KGaAin August 2010.
Mel Booth is a Certified Public Accountant.